Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell …
OBJECTIVE: To compare the effectiveness and cost-effectiveness of erlotinib versus gefitinib
as first-line treatment of epidermal growth factor receptor-activating mutation-positive non …
as first-line treatment of epidermal growth factor receptor-activating mutation-positive non …
[HTML][HTML] Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene …
P Krawczyk, DM Kowalski, R Ramlau… - Oncology …, 2017 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
[HTML][HTML] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients …
G Chen, J Feng, C Zhou, YL Wu, XQ Liu, C Wang… - Annals of …, 2013 - Elsevier
Background The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …
[HTML][HTML] Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
AS Wong, R Soong, SBK Seah, SW Lim… - Journal of Thoracic …, 2008 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer …
Background Epidermal growth factor receptor (EGFR) mutations are associated with
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
Objective Patients with advanced non-small-cell lung cancer (NSCLC) with an
adenocarcinoma component are recommended to undergo epidermal growth factor receptor …
adenocarcinoma component are recommended to undergo epidermal growth factor receptor …
EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.
R Rosell, MA Molina-Vila, M Taron, J Bertran-Alamillo… - 2012 - ascopubs.org
7522 Background: When EGFR compound mutants (exon 19 deletions or L858R
plusT790M) are present at the time of clinical resistance to erlotinib, patients attain longer …
plusT790M) are present at the time of clinical resistance to erlotinib, patients attain longer …
Advanced EGFR mutation-positive Non–small-cell lung cancer: case report, literature review, and treatment recommendations
A Kuykendall, A Chiappori - Cancer Control, 2014 - journals.sagepub.com
Background: Lung cancer is the leading cause of cancer mortality. Non–small-cell lung
cancer (NSCLC) comprises up to 90% of all lung cancers. Conventional treatment for …
cancer (NSCLC) comprises up to 90% of all lung cancers. Conventional treatment for …
Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer: A multicenter phase 2 trial
S Miyamoto, K Azuma, H Ishii, A Bessho… - JAMA …, 2020 - jamanetwork.com
Importance Although the efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
M Maemondo, T Fukuhara, H Saito, N Furuya… - 2020 - ascopubs.org
9506 Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …